Brief: Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock
22/05/2025 21:27
Gyre Therapeutics Inc GYRE.O: GYRE THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK GYRE THERAPEUTICS INC - PROCEEDS TO ADVANCE PHASE 2 TRIAL OF F351 IN MASH-ASSOCIATED LIVER FIBROSIS Source text: ID:nGNX8r7HbT Further company coverage: GYRE.O
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes